{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:32:14Z","timestamp":1792636334266,"version":"4.5.0"},"reference-count":50,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,1,21]],"date-time":"2018-01-21T00:00:00Z","timestamp":1516492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Myasthenia gravis (MG) with antibodies to muscle\u2010specific kinase (MuSK) is characterized by fluctuating fatigable weakness. In MuSK MG, involvement of bulbar muscles, neck, and shoulder and respiratory weakness are more prominent than in acetylcholine receptor (AChR) MG. MuSK autoantibodies are mainly of the IgG4 subclass, and as such are unable to activate complement, have low affinity for Fc receptors, and are functionally monovalent. Therefore, the pathogenicity of IgG4 MuSK autoantibodies was initially questioned. A broad collection of\n                    <jats:italic>in vitro<\/jats:italic>\n                    active immunization and passive transfer models has been developed that have shed light on the pathogenicity of MuSK autoantibodies. Passive transfer studies with purified IgG4 from MuSK MG patients confirmed that IgG4 is sufficient to reproduce clear clinical, electrophysiological, and histological signs of myasthenia.\n                    <jats:italic>In vitro<\/jats:italic>\n                    experiments revealed that MuSK IgG4 autoantibodies preferably bind the first Ig\u2010like domain of MuSK, correlate with disease severity, and interfere with the association between MuSK and low\u2010density lipoprotein receptor\u2013related protein 4 and collagen Q. Some patients have additional IgG1 MuSK autoantibodies, but their role in the disease is unclear. Altogether, this provides a rationale for epitope\u2010specific or IgG4\u2010specific treatment strategies for MuSK MG and emphasizes the importance of the development of different experimental models.\n                  <\/jats:p>","DOI":"10.1111\/nyas.13543","type":"journal-article","created":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T09:58:41Z","timestamp":1516615121000},"page":"111-118","source":"Crossref","is-referenced-by-count":12,"title":["Passive transfer models of myasthenia gravis with muscle\u2010specific kinase antibodies"],"prefix":"10.1111","volume":"1413","author":[{"given":"Jan J.G.M.","family":"Verschuuren","sequence":"first","affiliation":[{"name":"Department of Neurology Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap J.","family":"Plomp","sequence":"additional","affiliation":[{"name":"Department of Neurology Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve J.","family":"Burden","sequence":"additional","affiliation":[{"name":"Kimmel Center for Biology and Medicine at the Skirball Institute New York University Medical School  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Kimmel Center for Biology and Medicine at the Skirball Institute New York University Medical School  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne E.","family":"Filli\u00e9\u2010Grijpma","sequence":"additional","affiliation":[{"name":"Department of Neurology Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge E.","family":"Stienstra\u2010van Es","sequence":"additional","affiliation":[{"name":"Department of Neurology Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik H.","family":"Niks","sequence":"additional","affiliation":[{"name":"Department of Neurology Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Losen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience Maastricht University  Maastricht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silv\u00e8re M.","family":"van der Maarel","sequence":"additional","affiliation":[{"name":"Department of Neurology Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje G.","family":"Huijbers","sequence":"additional","affiliation":[{"name":"Department of Neurology Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg223"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-315782"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2010.07569.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22006"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta\u2010analysis","volume":"62","author":"Iorio R.","year":"2015","journal-title":"J. Neurol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009167"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81251-9"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2005.10.020"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddh333"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq110"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81252-0"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.7.2895"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880171208"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2006.03.016"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21545"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20061"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20341"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21642"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000228225.23349.5d"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.12.016"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.01.013"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e3181f8a9aa"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000307751.20968.f1"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0140-6736(86)92259-2","article-title":"Myasthenia gravis without acetylcholine\u2010receptor antibody: a distinct disease entity","volume":"1","author":"Mossman S.","year":"1986","journal-title":"Lancet"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.052415"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.020"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880171208"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21371"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.090040"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318237f660"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws025"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.11.005"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20061"},{"key":"e_1_2_7_36_1","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti\u2010inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"der Neut K.M.","year":"2007","journal-title":"Science"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2012.01.025"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2013.270207"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2012.06.034"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2015.01.007"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080695"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8206.1"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2013.251827"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70245-9"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2012.11.004"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22153"},{"key":"e_1_2_7_48_1","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010028.pub2","article-title":"Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes","author":"Vrinten C.","year":"2014","journal-title":"Cochrane Database Syst. Rev"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.11.009"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087840"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12658"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnyas.13543","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nyas.13543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T10:44:35Z","timestamp":1694601875000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/nyas.13543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,21]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/nyas.13543"],"URL":"https:\/\/doi.org\/10.1111\/nyas.13543","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,21]]}}}